EUVIMEDEUVIMED entdecken
Crossref

PDIA5 and ARFIP1 as Immunogenetic Biomarkers and Therapeutic Targets in Pancreatic Neuroendocrine Neoplasms: A Multi-Omics Study Integrating MR, Gene Expression Microarray, and Single-Cell Transcriptomics

Huimin Guo, Guiwen Zheng, Shuzhan Yao, Qiang Jia, Jian Tan, Zhaowei Meng

Neuroendocrinology · 2025

DOI: 10.1159/000548070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuroendocrinology, 2025. Verfasst von Huimin Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor, Neuroendocrine Tumors. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pancreatic neuroendocrine neoplasms (PanNENs) are characterized by significant clinical heterogeneity and limited therapeutic options, particularly in metastatic or recurrent cases. Identifying actionable molecular targets and biomarkers is essential for improving patient outcomes.

Methods

We employed a multi-omics approach to identify biomarkers and therapeutic targets for PanNENs. Two-sample Mendelian randomization (TSMR) was conducted using plasma proteome data from [Nat Genet. 2020;52(10):1122–31] and deCODE. Differential expression and weighted gene co-expression network analyses (WGCNA) were performed on the GSE73338 dataset to prioritize biomarkers. Validation included cis-expression quantitative trait loci (cis-eQTL) data from eQTLGen and summary data-based MR (SMR) with heterogeneity in dependent instrument (HEIDI) tests. Immune mediation analysis was performed, followed by transcriptomic validation using gene expression microarrays (GSE43795) and single-cell RNA sequencing (GSE256136) data. Immune infiltration was assessed using CIBERSORT, and protein expression was validated using immunohistochemistry. Pan-cancer analysis was conducted using TCGA and GTEx data, and diagnostic performance was evaluated using ROC curves and nomograms.

Results

PDIA5 and ARFIP1 were identified as potential biomarkers and therapeutic targets for PanNENs. Both proteins were upregulated in PanNEN tissues and showed consistent associations with PanNEN risk through TSMR and SMR analyses. Immune mediation analysis suggested their involvement in immune modulation. Pan-cancer analysis revealed their overexpression in multiple cancer types. Diagnostic performance, evaluated using ROC curves, demonstrated the strong potential of PDIA5 and ARFIP1 in PanNEN diagnosis.

Conclusion

PDIA5 and ARFIP1 are promising biomarkers and therapeutic targets for PanNEN. Further validation and clinical exploration are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsBiomarkers, TumorNeuroendocrine TumorsHumansGene Expression ProfilingSingle-Cell AnalysisMendelian Randomization AnalysisTranscriptomeQuantitative Trait LociMultiomics

Stichwörter der Autor:innen

BiomarkersImmune modulationMendelian randomizationPancreatic neuroendocrine neoplasmsSingle-cell RNA sequencingTherapeutic targetsWeighted gene co-expression network analyses

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Tianjin Key Lab of Functional Imaging and Tianjin Institute of Radiology, Tianjin Medical University General Hospital, Tianjin, China.

Zitieren

APA

Guo, H., Zheng, G., Yao, S., Jia, Q., Tan, J., & Meng, Z. (2025). PDIA5 and ARFIP1 as Immunogenetic Biomarkers and Therapeutic Targets in Pancreatic Neuroendocrine Neoplasms: A Multi-Omics Study Integrating MR, Gene Expression Microarray, and Single-Cell Transcriptomics. Neuroendocrinology. https://doi.org/10.1159/000548070

Vancouver

Guo H, Zheng G, Yao S, Jia Q, Tan J, Meng Z. PDIA5 and ARFIP1 as Immunogenetic Biomarkers and Therapeutic Targets in Pancreatic Neuroendocrine Neoplasms: A Multi-Omics Study Integrating MR, Gene Expression Microarray, and Single-Cell Transcriptomics. Neuroendocrinology. 2025. doi:10.1159/000548070

BibTeX
@article{Guo2025,
  author = {Guo, Huimin and Zheng, Guiwen and Yao, Shuzhan and Jia, Qiang and Tan, Jian and Meng, Zhaowei},
  title = {PDIA5 and ARFIP1 as Immunogenetic Biomarkers and Therapeutic Targets in Pancreatic Neuroendocrine Neoplasms: A Multi-Omics Study Integrating MR, Gene Expression Microarray, and Single-Cell Transcriptomics},
  journal = {Neuroendocrinology},
  year = {2025},
  doi = {10.1159/000548070}
}
Kostenlos starten →